多发性骨髓瘤中双特异性抗体治疗后的感染:系统综述与meta分析
本系统综述与meta分析检索MEDLINE、EMBASE和Cochrane数据库至2023年2月10日,纳入16项临床试验共1666例多发性骨髓瘤患者,评估双特异性抗体治疗后的感染风险。汇总全级别感染患病率为56%,≥3级感染为24%;BCMA靶向双特异性抗体较非BCMA者≥3级感染率显著更高(25% vs 20%),联合治疗较单药全级别感染率显著更高(71% vs 52%)。
要点
- 双特异性抗体治疗后全级别感染患病率56%,≥3级感染患病率24%。
- BCMA靶向双特异性抗体≥3级感染率25%,高于非BCMA者的20%。
- 双特异性抗体联合其他药物全级别感染率71%,高于单药治疗的52%。
核心结论
- BCMA靶向双特异性抗体和双特异性抗体联合治疗具有更高的感染风险,需要警惕性感染筛查和预防策略。
研究设计与样本
- 系统综述与meta分析,检索MEDLINE、EMBASE和Cochrane数据库从建库至2023年2月10日的文献,包括主要会议报告。
- 纳入1b-3期临床试验和观察性研究。
- 共纳入16项临床试验,包含1666例患者;中位随访7.6个月,38%的患者为五药难治性疾病。
- 观察性研究(n=293)被排除在主要分析之外,以确保与临床试验患者无重叠。
主要发现
- 全级别感染的汇总患病率为56%,≥3级感染的患病率为24%。
- 接受BCMA靶向双特异性抗体治疗的患者≥3级感染率显著高于非BCMA双特异性抗体(25% vs 20%)。
- 接受双特异性抗体联合其他药物治疗的患者全级别感染率显著高于单药治疗(71% vs 52%)。
- 在观察性研究(n=293)中,识别出几种经典与T细胞耗竭相关的感染。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface marker CD3 and malignant cell markers, including B-cell maturation antigen (BCMA), FcRH5, and G protein-coupled receptor GPRC5D. These bispecific antibodies so effectively deplete plasma cells (and to some extent T-cells) that patients are at increased risk of developing infections. A systematic review and meta-analysis of infections in published studies of patients with myeloma treated with bispecific antibodies was conducted to better characterize the infection risks. A literature search used MEDLINE, EMBASE, and Cochrane to identify relevant studies between inception and February 10, 2023, including major conference presentations. Phase 1b-3 clinical trials and observational studies were included. Sixteen clinical trials comprising 1666 patients were included. Median follow-up was 7.6 months and 38% of the cohort had penta-drug refractory disease. Pooled prevalence of all-grade infections was 56%, whereas the prevalence of grade ≥3 infections was 24%. Patients who were treated with BCMA-targeted bispecifics had significantly higher rates of grade ≥3 infections than non-BCMA bispecifics (25% vs 20%). Similarly, patients treated with bispecifics in combination with other agents had significantly higher rate of all-grade infection than those receiving monotherapy (71% vs 52%). In observational studies (n = 293), excluded from the primary analysis to ensure no overlap with patients in clinical trials, several infections classically associated with T-cell depletion were identified. This systematic review identifies BCMA-targeted bispecifics and bispecific combination therapy as having higher infection risk, requiring vigilant infection screening and prophylaxis strategies.
引用
- Reynolds G, Cliff ERS, Mohyuddin GR, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023. PMID: 37467036. doi:10.1182/bloodadvances.2023010539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。